Alexei Zelenev1, Portia Shea2, Alyona Mazhnaya3, Julia Rozanova2, Lynn Madden4, Ruthanne Marcus2, Frederick L Altice5. 1. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA. Electronic address: alexei.zelenev@yale.edu. 2. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA. 3. ICF Alliance for Public Health in Ukraine. 5 Dilova str. Building 10A, Kyiv 03150, Ukraine; Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior and Society. 624 N Broadway, Baltimore, MD 21205, USA. 4. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; APT Foundation, New Haven, CT, USA. 5. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, New Haven, CT, USA.
Abstract
BACKGROUND: Opioid agonist therapies (OAT) in Ukraine were first introduced in 2004 not as addiction treatment, but for HIV prevention. Numerous obstacles have thwarted OAT scale-up, including individual constraints and structural barriers. METHODS: A cross-sectional survey of 1613 opioid dependent people who inject drugs (PWID) were recruited in 2014-2015 using stratified sampling in Kyiv, Odesa, Mykolayiv, Dnipro and Lviv. Analysis was restricted to a subset of 811 PWID who never received OAT. Barriers to OAT were assessed based on reasons why study participants were reluctant to enroll into OAT. A Rasch model from the Item Response Theory was applied to 24 potential barriers, used to score their severity and estimate a latent composite measure for each person's willingness and ability to participate in OAT. RESULTS: The Rasch model confirmed the cumulative nature of barriers with concerns over treatment efficacy, safety and tolerability being more prevalent than barriers related to logistical constraints, opportunity costs and social stigma. If barriers related to treatment perception and logistics were eliminated, the average barrier number would decrease from 10 to 2.2. Participants were more likely to have a higher resistance to OAT entry if they experienced fewer overdoses, did not attain higher education, were not previously incarcerated and if their peers did not have a higher level of resistance to OAT. CONCLUSIONS: Understanding the interdependence of various barriers and attitudes toward OAT can improve the rate of OAT expansion and ameliorate entry into substance abuse treatment programs in Ukraine.
BACKGROUND: Opioid agonist therapies (OAT) in Ukraine were first introduced in 2004 not as addiction treatment, but for HIV prevention. Numerous obstacles have thwarted OAT scale-up, including individual constraints and structural barriers. METHODS: A cross-sectional survey of 1613 opioid dependent people who inject drugs (PWID) were recruited in 2014-2015 using stratified sampling in Kyiv, Odesa, Mykolayiv, Dnipro and Lviv. Analysis was restricted to a subset of 811 PWID who never received OAT. Barriers to OAT were assessed based on reasons why study participants were reluctant to enroll into OAT. A Rasch model from the Item Response Theory was applied to 24 potential barriers, used to score their severity and estimate a latent composite measure for each person's willingness and ability to participate in OAT. RESULTS: The Rasch model confirmed the cumulative nature of barriers with concerns over treatment efficacy, safety and tolerability being more prevalent than barriers related to logistical constraints, opportunity costs and social stigma. If barriers related to treatment perception and logistics were eliminated, the average barrier number would decrease from 10 to 2.2. Participants were more likely to have a higher resistance to OAT entry if they experienced fewer overdoses, did not attain higher education, were not previously incarcerated and if their peers did not have a higher level of resistance to OAT. CONCLUSIONS: Understanding the interdependence of various barriers and attitudes toward OAT can improve the rate of OAT expansion and ameliorate entry into substance abuse treatment programs in Ukraine.
Authors: Louisa Degenhardt; Bradley M Mathers; Andrea L Wirtz; Daniel Wolfe; Adeeba Kamarulzaman; M Patrizia Carrieri; Steffanie A Strathdee; Kasia Malinowska-Sempruch; Michel Kazatchkine; Chris Beyrer Journal: Int J Drug Policy Date: 2013-09-04
Authors: Victor A Capoccia; Frances Cotter; David H Gustafson; Elaine F Cassidy; James H Ford; Lynn Madden; Betta H Owens; Scott O Farnum; Dennis McCarty; Todd Molfenter Journal: Jt Comm J Qual Patient Saf Date: 2007-02
Authors: Michael King; Irwin Nazareth; Fiona Lampe; Peter Bower; Martin Chandler; Maria Morou; Bonnie Sibbald; Rosalind Lai Journal: JAMA Date: 2005-03-02 Impact factor: 56.272
Authors: R S Broadhead; D D Heckathorn; D L Weakliem; D L Anthony; H Madray; R J Mills; J Hughes Journal: Public Health Rep Date: 1998-06 Impact factor: 2.792
Authors: Lynn M Madden; Scott O Farnum; Kathryn F Eggert; Andrew R Quanbeck; Robert M Freeman; Samuel A Ball; Richard S Schottenfeld; Julia M Shi; Mary Ellen Savage; Declan T Barry Journal: Addiction Date: 2018-03-24 Impact factor: 6.526
Authors: Harry Jin; Brandon D L Marshall; Louisa Degenhardt; John Strang; Matt Hickman; David A Fiellin; Robert Ali; Julie Bruneau; Sarah Larney Journal: Addiction Date: 2020-05-19 Impact factor: 6.526
Authors: Kathryn E Lancaster; Irving F Hoffman; Brett Hanscom; Tran Viet Ha; Kostyantyn Dumchev; Hepa Susami; Scott Rose; Vivian F Go; Sarah A Reifeis; Katie R Mollan; Michael G Hudgens; Estelle M Piwowar-Manning; Paul Richardson; Sergii Dvoriak; Zubairi Djoerban; Tetiana Kiriazova; Oleksandr Zeziulin; Samsuridjal Djauzi; Chu Viet Ahn; Carl Latkin; David Metzger; David N Burns; Jeremy Sugarman; Steffanie A Strathdee; Susan H Eshleman; William Clarke; Deborah Donnell; Lynda Emel; Lisa E Sunner; Laura McKinstry; Nirupama Sista; Erica L Hamilton; Jonathan P Lucas; Bui D Duong; Nguyen Van Vuong; Riza Sarasvita; William C Miller Journal: J Int AIDS Soc Date: 2018-10 Impact factor: 5.396
Authors: Tetiana Kiriazova; Vivian F Go; Rebecca B Hershow; Erica L Hamilton; Riza Sarasvita; Quynh Bui; Kathryn E Lancaster; Kostyantyn Dumchev; Irving F Hoffman; William C Miller; Carl A Latkin Journal: Harm Reduct J Date: 2020-10-01